🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07672964
Starting soon Phase 1

CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation

NCT07672964 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Phase 1
Started
2026-07-01
Last updated
2026-06-29

Condition(s) studied

Hematologic MalignancyHaplo-identical HCT

Investigational drug(s) / intervention(s)

CD45RA-depleted DLI

CD45RA-depleted DLI: CD45RA Depleted DLI by ex vivo CliniMACS® prepared from mononuclear cell leukapheresis

Study summary

The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are:

Does this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?

Eligibility

Sex
ALL
Min age
14 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: Participants must meet all of the following criteria: * Patients undergoing allogeneic hematopoietic stem cell transplantation (any conditioning regimen or graft source is allowed). * Presence of at least one high-risk factor for post-transplant viral infection (any of the following): * Age ≥50 years or ≤14 years * Non-sibling matched transplantation * In vivo or ex vivo T-cell depletion * Myeloablative conditioning * Conditioning containing radiotherapy * Second transplantation * CMV IgG or EBV IgG donor/recipient mismatch (donor positive, recipient negative) * History of grade II or higher acute graft-versus-host disease (aGVHD) after transplantation and use of high-dose corticosteroids (prednisone equivalent ≥1 mg/kg/day) * Availability of a suitable lymphocyte donor (see "Donor Selection Criteria"). * Adequate organ function meeting the following laboratory criteria: * Liver function: ALT and AST ≤10× upper limit of normal (ULN); total bilirubin ≤5× ULN * Renal function: BUN and creatinine ≤1.25× ULN * No cardiac dysfunction on electrocardiogram or echocardiogram * Pulmonary function: oxygen saturation \>90% without supplemental oxygen * The patient or legal guardian has the desire and request to receive treatment, signs the informed consent form before treatment, and is willing to comply with the treatment plan, follow-up schedule, and laboratory tests. Exclusion Criteria: Patients meeting any of the following criteria will be excluded from this study: * Active grade II-IV acute graft-versus-host disease (aGVHD) * Active aGVHD requiring prednisone or equivalent corticosteroid \>0.5 mg/kg/day * Active viral infection * Uncontrolled or relapsed malignancy * Other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or affect informed consent, study participation, follow-up, or interpretation of results.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital Shanghai SH

More Ruijin Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07672964 on ClinicalTrials.gov ↗ ← All trials in China